AbCellera Biologics Inc. (ABCL) is priced at $28.35 after the most recent trading session. At the very opening of the session, the stock price was $29.96 and reached a high price of $30.75, prior to closing the session it reached the value of $30.59. The stock touched a low price of $27.61.
Recently in News on April 5, 2021, Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19. – Bamlanivimab (LY-CoV555) has greater affinity and potency relative to other RBD-binding and ACE2-blocking antibodies tested in this study. You can read further details here
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, AbCellera Biologics Inc. shares are logging -60.58% during the 52-week period from high price, and 22.20% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $23.20 and $71.91.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2375454 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the AbCellera Biologics Inc. (ABCL) recorded performance in the market was -29.55%, having the revenues showcasing -27.90% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 8.24B, as it employees total of 206 workers.
AbCellera Biologics Inc. (ABCL) in the eye of market guru’s
During the last month, 1 analysts gave the AbCellera Biologics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ABCL is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
AbCellera Biologics Inc. (ABCL): Stocks Technical analysis and Trends
Raw Stochastic average of AbCellera Biologics Inc. in the period of last 50 days is set at 16.08%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 32.21%. In the last 20 days, the company’s Stochastic %K was 43.01% and its Stochastic %D was recorded 42.17%.
If we look into the earlier routines of AbCellera Biologics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -29.55%. The shares increased approximately by -7.68% in the 7-day charts and went up by -12.01% in the period of the last 30 days. Common stock shares were lifted by -27.90% during last recorded quarter.